ArticleRSC advances2017
Comparison of macrocyclic and acyclic chelators for gallium-68 radiolabelling.
Article in RSC advances, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 165 citations in OpenAlex.
- Preliminary evaluation of a novel PSMA-targeting radiopharmaceutical [European journal of nuclear medicine and molecular imaging · 2025Trial
- Biodistribution, dosimetry, and temporal signal-to-noise ratio analyses of normal and cancer uptake of [Nuclear medicine and biologyTrial
- ExpandingEJNMMI radiopharmacy and chemistry · 2026Article
- EfficientInternational journal of molecular sciences · 2026Article
- Synthesis, crystal structure, and Hirshfeld surface analysis of bis-{2-[(Acta crystallographica. Section E, Crystallographic communications · 2026Article
- Influences of Ring Sizes and Chiral Substituents on Macrocyclic Chelators for ImprovingJACS Au · 2026Article
- Challenges and Opportunities in Radioligand Therapy.Journal of nuclear medicine technology · 2025Review
- Establishment and validation of an alternative automated synthesis of [68Ga]Ga-DOTA-Siglec-9 in an independent laboratory for clinical use.EJNMMI radiopharmacy and chemistry · 2025Article
- Thwarting Isomerization through Rigidity: A Promising HBED Derivative for the Chelation of Gallium-68.Inorganic chemistry · 2025Article
- Preclinical evaluation of [EJNMMI radiopharmacy and chemistry · 2025Article
- Minimising the impact of stableEJNMMI radiopharmacy and chemistry · 2025Article
- Article
- Review
- Selection of the optimal chelator for labeling of DARPin Ec1 with gallium-68 for PET imaging of EpCAM expression.EJNMMI radiopharmacy and chemistry · 2025Article
- New Radiopharmaceutical Tracers in Breast Cancer Diagnosis and Therapy.Anti-cancer agents in medicinal chemistry · 2025Review
- Value of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- Towards a General Method for Using Cyclotron-Produced Ga68 to Manufacture Clinical and Research Ga68 Tracers.Molecules (Basel, Switzerland) · 2024Article
- Evaluation of [Pharmaceuticals (Basel, Switzerland) · 2024Article
- Versatile Diphosphine Chelators for Radiolabeling Peptides withInorganic chemistry · 2023Article
- Radiometal-Labeled Photoactivatable Pt(IV) Anticancer Complex for Theranostic Phototherapy.Inorganic chemistry · 2023Article
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 5 countries.
Funding
Abstract
Gallium-68 (
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.